Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors

被引:28
作者
Anandan, Sampath-Kumar [1 ]
Do, Zung N. [1 ]
Webb, Heather K. [1 ]
Patel, Dinesh V. [1 ]
Gless, Richard D. [1 ]
机构
[1] Arete Therapeut Inc, Hayward, CA 94545 USA
关键词
sEH inhibitors; Non-urea; Primary pharmacophore; 1,3-DISUBSTITUTED UREAS; THERAPEUTIC TARGET; POTENT INHIBITORS; WATER SOLUBILITY; HYPERTENSION; STROKE;
D O I
10.1016/j.bmcl.2009.01.013
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1066 / 1070
页数:5
相关论文
共 22 条
[21]   Development of a high-throughput screen for soluble epoxide hydrolase inhibition [J].
Wolf, Nicola M. ;
Morisseau, Christophe ;
Jones, Paul D. ;
Hock, Bertold ;
Hammock, Bruce D. .
ANALYTICAL BIOCHEMISTRY, 2006, 355 (01) :71-80
[22]   Soluble epoxide hydrolase: a novel therapeutic target in stroke [J].
Zhang, Wenri ;
Koerner, Ines P. ;
Noppens, Ruediger ;
Grafe, Marjorie ;
Tsai, Hsing-Ju ;
Morisseau, Christophe ;
Luria, Ayala ;
Hammock, Bruce D. ;
Falck, John R. ;
Alkayed, Nabil J. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2007, 27 (12) :1931-1940